Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis

Japanese Journal of Infectious Diseases

Volumn 64, Issue 6, 2011, Pages 509-512

  Tang, Shen Jie ^a,b   Zhang, Qing ^a,b   Zeng, Lin Hai ^a,b   Sun, Hua ^a,b   Gu, Jin ^a,b   Hao, Xiao Hui ^a,b   Liu, Yi Dian ^a,b   Yao, Lan ^a,b   Xiao, He Ping ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Tuberculosis   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LINEZOLID; MECOBALAMIN; PROTIONAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD TOXICITY; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FEVER; HEMOPTYSIS; HUMAN; HYPOPROTEINEMIA; HYPOXEMIA; LUNG TUBERCULOSIS; MALE; NAUSEA; NEUTROPENIA; OPTIC NERVE DISEASE; PARESTHESIA; PERIPHERAL NEUROPATHY; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUBERCULOUS PLEURISY; VISUAL IMPAIRMENT;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG MONITORING; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; RADIOGRAPHY, THORACIC; SPUTUM; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 82355164493     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Tang, S.J. and Xiao, H.P. (2009): Advances in the study of extensively drug resistant tuberculosis. Chin. J. Tuber. Respir. Dis., 32, 380-383 (text in Chinese with English summary).
2. World Health Organization (2010): Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3.
3. Sotgiu, G., Ferrara, G., Matteelli, A., et al. (2009): Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J., 33, 871-881.
4. Migliori, G.B., Lange, C., Centis, R., et al. (2008): Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J., 31, 1155-1159.
5. Schecter, G.F., Scott, C., True, L., et al. (2010): Linezolid in the treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis., 50, 49-55.
6. Brown-Elliott, B.A., Crist, C.J., Mann, L.B., et al. (2003): In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob. Agents Chemother., 47, 1736-1738.
7. Prammananan, T., Chaiprasert, A. and Leechawengwongs, M. (2009): In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates. Int. J. Antimicrob. Agents, 33, 190-191.
8. Huang, T.S., Liu, Y.C., Sy, C.L., et al. (2008): In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob. Agents Chemother., 52, 2226-2227.
9. Condos, R., Hadgiangelis, N., Leibert, E., et al. (2008): Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest, 134, 187-192.
10. Anger, H.A., Dworkin, F., Sharma, S., et al. (2010): Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J. Antimicrob. Chemother., 65, 775-783.
11. World Health Organization (2008): Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. WHO/HTM/TB/2008.402.
12. World Health Organization (2008): Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2008. WHO/ HTM/TB/2008.393.
13. Tang, S., Zhang, Q., Yu, J., et al. (2011): Extensively drugresistant tuberculosis, China. Emerg. Infect. Dis., 17, 558-560.
14. Nam, H.S., Koh, W.J. and Kwon, O.J. (2009): Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int. J. Antimicrob. Agents, 33, 92-93.
15. Migliori, G.B., Eker, B., Richardson, M.D., et al. (2009): A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J., 34, 387-393.
16. Koh, W.J., Kwon, O.J., Gwak, H., et al. (2009): Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother., 64, 388-391.
17. Park, I.N., Hong, S.B., Oh, Y.M., et al. (2006): Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother., 58, 701-704.